Abstract

Radiation nephropathy and other normal tissue radiation injuries can be successfully mitigated, and also treated, by antagonists of the renin-angiotensin system (RAS). This implies a mechanistic role for that system in radiation nephropathy, yet no evidence exists to date of activation of the RAS by irradiation. RAS antagonists, including angiotensin converting enzyme inhibitors and angiotensin receptor blockers, are the standard of care in the treatment of subjects with other chronic progressive kidney diseases, in which they exert benefit by reducing both glomerular and tubulo-interstitial injury. These drugs are likely to act in a similar way to mitigate radiation nephropathy.

Keywords: Radiation injuries, radiation nephropathy, renin-angiotensin system, angiotensins, captopril, mesangiolysis, Radiation, nephropathy, angiotensin, (TBI), (BMT), Mitigation, (ACE), (BUN), (DMFs), losartan, (HSCT), RAS, (NO), (AcSDKP), bradykinin, (AVE0991), DNA, NADPH oxidase, glomerular